Omicron sublineage BA.2.75.2 exhibits extensive escape from neutralising antibodies-Reference-Cited by-同舟云学术

Omicron sublineage BA.2.75.2 exhibits extensive escape from neutralising antibodies

Published:2022-11 Issue:11 Volume:22 Page:1538-1540
ISSN:1473-3099
Container-title:The Lancet Infectious Diseases
language:en
Short-container-title:The Lancet Infectious Diseases

Author:

Sheward Daniel J,Kim Changil,Fischbach Julian,Sato Kenta,Muschiol Sandra,Ehling Roy A,Björkström Niklas K,Hedestam Gunilla B Karlsson,Reddy Sai T,Albert Jan,Peacock Thomas P,Murrell Ben

Publisher

Elsevier BV

Subject

Infectious Diseases

Reference7 articles.

1. Characterization of the enhanced infectivity and antibody evasion of Omicron BA.2.75;Cao;Cell Host Microbe,2022

2. Evasion of neutralising antibodies by omicron sublineage BA.2.75;Sheward;Lancet Infect Dis,2022

3. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection;Cao;Nature,2022

4. Characterization of the SARS-CoV-2 B.1.621 (Mu) variant;Halfmann;Sci Transl Med,2022

5. Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization;Cele;Nature,2021

Cited by 64 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antigenic sin and multiple breakthrough infections drive converging evolution of COVID-19 neutralizing responses;Cell Reports;2024-09

2. Coronaviruses have Reached at Pre-Elimination Stage with nine amino acids spike deletions and forty-nine nucleotides 3’-UTR deletion;2024-08-21

3. Multi-compartmental diversification of neutralizing antibody lineages dissected in SARS-CoV-2 spike-immunized macaques;Nature Communications;2024-07-27

4. Safety, tolerability and pharmacokinetics of ASC10, a novel oral double prodrug of a broad-spectrum antiviral agent, β-d-N4-hydroxycytidine: results from a randomized, double-blind, placebo-controlled phase 1 study in Chinese healthy subjects;Expert Opinion on Investigational Drugs;2024-07-12

5. Structural basis of broad SARS-CoV-2 cross-neutralization by affinity-matured public antibodies;Cell Reports Medicine;2024-06